| DB ID | MyCo_5469 |
| Title | COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory |
| Year | 2020 |
| PMID | 33087440 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | COVID-19 patients |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | Samples were included in the current study only if the corresponding patient had been admitted to an ICU and had tested positive by RT-PCR for SARS-CoV-2 RNA. Samples from patients who had a clinical diagnosis of COVID-19 but repeatedly tested negative for SARS-CoV-2 were excluded. Between 11 March and 14 July 2020, the MRL received a total of 1,267 diagnostic specimens (1,178 serum samples and 89 respiratory specimens) from 719 critically ill UK patients diagnosed with COVID-19. Serum samples were subjected to BDG or GM testing as indicated by the requesting physician. |
| Cohort No. | 719 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) complicating severe influenza pneumonia is well described from anecdotal case reports, and more recently from cross-center and large cohort studies. Of particular note, mortality was significantly higher in patients with influenza/aspergillosis than in those with influenza alone. There exists significant variation in the reported incidence of IA in critically ill influenza patients, with incidence rates between 7.2 and 28.1% reported from different studies. These variations in calculated incidence are likely to reflect a combination of real regional differences in Aspergillus predominance/exposure, variable access to different diagnostic testing regimens, different clinical approaches to managing influenza patients in intensive care units (ICUs) and diagnosing IA, and variations in awareness of influenza-associated pulmonary aspergillosis (IAPA). |
| Technique | PCR |
| Analysis Method | Aspergillus PCR |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA approved Fungitell assay, ELISA Based, PCR Based |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
